Please note the ANZCTR will be unattended from Friday 20 December 2019 for the holidays. The Registry will re-open on Tuesday 07 January 2020. Submissions and updates will not be processed during that time.

Please be advised that as the ANZCTR is funded by Australia and New Zealand, we must prioritise submissions from these countries first. International submissions should allow additional time for registration. Apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00594568




Registration number
NCT00594568
Ethics application status
Date submitted
11/01/2008
Date registered
15/01/2008
Date last updated
17/03/2015

Titles & IDs
Public title
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Scientific title
Effect of ?-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo
Secondary ID [1] 0 0
H6L-MC-LFAN
Secondary ID [2] 0 0
7666
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LY450139
Treatment: Drugs - Placebo

Placebo Comparator: Placebo - Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.

Experimental: 100 mg LY450139 - Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.

Experimental: 140 mg LY450139 - Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.


Treatment: Drugs: LY450139
Administered orally once daily

Treatment: Drugs: Placebo
Administered orally once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks - ADAS-Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [1] 0 0
Baseline (randomization), 76 weeks
Primary outcome [2] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug - ADAS-Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [2] 0 0
Baseline (randomization), 16 weeks following treatment cessation
Primary outcome [3] 0 0
Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks - ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [3] 0 0
Baseline (randomization), 76 weeks
Primary outcome [4] 0 0
Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug - ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [4] 0 0
Baseline (randomization), 16 weeks following treatment cessation
Secondary outcome [1] 0 0
Percent Change From Baseline in Amyloid Beta (Aß) 1-42 Plasma Concentration at 52 Weeks - Concentration of amino acid peptide, known as Aß 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [1] 0 0
Baseline (randomization), 52 weeks
Secondary outcome [2] 0 0
Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks - Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [2] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [3] 0 0
Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks - The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [3] 0 0
Baseline (randomization), up to 76 weeks
Secondary outcome [4] 0 0
Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks - A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [4] 0 0
Baseline (randomization), up to 76 weeks
Secondary outcome [5] 0 0
Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks - Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [5] 0 0
Baseline (randomization), up to 76 weeks
Secondary outcome [6] 0 0
LY450139 Population Pharmacokinetics: Clearance of LY450139 - Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time.
Timepoint [6] 0 0
6 weeks, 12 weeks, and 52 weeks
Secondary outcome [7] 0 0
LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139 - Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body.
Timepoint [7] 0 0
6 weeks, 12 weeks, and 52 weeks
Secondary outcome [8] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks - ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [8] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [9] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks - ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.
Timepoint [9] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [10] 0 0
Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks - MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [10] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [11] 0 0
Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks - CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [11] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [12] 0 0
Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks - NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [12] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [13] 0 0
Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks - EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [13] 0 0
Baseline (randomization), 76 weeks
Secondary outcome [14] 0 0
Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks - Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator.
Timepoint [14] 0 0
Baseline (randomization), up to 76 weeks
Secondary outcome [15] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug - ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.
Timepoint [15] 0 0
Baseline (randomization), 16 weeks following treatment cessation
Secondary outcome [16] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug - ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.
Timepoint [16] 0 0
Baseline (randomization), 16 weeks following treatment cessation
Secondary outcome [17] 0 0
Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug - Semi-structured interview; Participant's cognitive status rated across 6 domains of functioning: memory, orientation, judgment/problem solving, community affairs, home/hobbies, personal care. Severity score assigned for each of 6 domains. Total score (SB) ranges: 0 to 18; Higher scores=greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants followed off-dose for 32 weeks, but CDR-SB not assessed.
Timepoint [17] 0 0
Baseline (randomization), 4 weeks following treatment cessation
Secondary outcome [18] 0 0
Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug - NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but NPI was not assessed
Timepoint [18] 0 0
Baseline (randomization), 4 weeks following treatment cessation
Secondary outcome [19] 0 0
Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug - MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, copy figures) in elderly participants. Total score ranges from 0 to 30; Lower score indicates greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but MMSE was not assessed.
Timepoint [19] 0 0
Baseline (randomization), 4 weeks following treatment cessation
Secondary outcome [20] 0 0
Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug - EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. VAS assesses caregiver's impression of participant's health state; score ranges from 0 to 100; Lower score indicates greater disease severity. LS Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but EQ-5D VAS was not assessed.
Timepoint [20] 0 0
Baseline (randomization), 4 weeks following treatment cessation
Secondary outcome [21] 0 0
Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug - RUD-Lite assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation, healthcare resource utilization) is collected. Reported number of participant hospitalizations. Least Squares (LS) Mean value controlled for age and investigator. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but RUD-Lite was not assessed.
Timepoint [21] 0 0
Baseline (randomization), 4 weeks following treatment cessation
Secondary outcome [22] 0 0
Change From Baseline in Amyloid Beta (Aß) 1-42 Concentration in Spinal Fluid up to 76 Weeks - Concentration of an amino peptide known as Aß 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [22] 0 0
Baseline (randomization), up to 76 weeks
Secondary outcome [23] 0 0
Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid - Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.
Timepoint [23] 0 0
Baseline (randomization), up to 76 weeks

Eligibility
Key inclusion criteria
- Meets criteria for mild to moderate Alzheimer's disease (AD) with Mini-Mental State
Examination (MMSE) score of 16-26 at Visit 1

- Modified Hachinski Ischemia Scale score of less than or equal to 4

- Geriatric Depression Scale score of less than or equal to 6

- A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2
years with no findings inconsistent with a diagnosis of AD

- If female, must be without menstruation for at least 12 consecutive months or have had
both ovaries removed
Minimum age
55 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Is not capable of swallowing whole oral medication

- Has serious or unstable illnesses

- Does not have a reliable caregiver

- Chronic alcohol or drug abuse within the past 5 years

- Has ever had active vaccination for AD

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Hornsby
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kogarah
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Randwick, Sydney
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Recruitment hospital [5] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Geelong
Recruitment hospital [6] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg West
Recruitment hospital [7] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kew
Recruitment hospital [8] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands
Recruitment postcode(s) [1] 0 0
2077 - Hornsby
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2013 - Randwick, Sydney
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
3220 - Geelong
Recruitment postcode(s) [6] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [7] 0 0
3101 - Kew
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Vermont
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Cordoba
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Belgium
State/province [28] 0 0
Aalst
Country [29] 0 0
Belgium
State/province [29] 0 0
Antwerp
Country [30] 0 0
Belgium
State/province [30] 0 0
Brugge
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Quebec
Country [34] 0 0
Chile
State/province [34] 0 0
Antofagasta
Country [35] 0 0
Chile
State/province [35] 0 0
Concepcion
Country [36] 0 0
Chile
State/province [36] 0 0
Santiago De Chile
Country [37] 0 0
Chile
State/province [37] 0 0
Santiago
Country [38] 0 0
Chile
State/province [38] 0 0
Valdivia
Country [39] 0 0
Chile
State/province [39] 0 0
Vina Del Mar
Country [40] 0 0
Denmark
State/province [40] 0 0
Kobenhavn
Country [41] 0 0
Denmark
State/province [41] 0 0
Roskilde
Country [42] 0 0
Denmark
State/province [42] 0 0
Svendborg
Country [43] 0 0
Finland
State/province [43] 0 0
Kuopio
Country [44] 0 0
Finland
State/province [44] 0 0
Mikkeli
Country [45] 0 0
Finland
State/province [45] 0 0
Oulu
Country [46] 0 0
France
State/province [46] 0 0
Nice
Country [47] 0 0
France
State/province [47] 0 0
Rennes
Country [48] 0 0
France
State/province [48] 0 0
Rouen
Country [49] 0 0
France
State/province [49] 0 0
Toulouse
Country [50] 0 0
France
State/province [50] 0 0
Tours
Country [51] 0 0
Germany
State/province [51] 0 0
Dresden
Country [52] 0 0
Germany
State/province [52] 0 0
Goettingen
Country [53] 0 0
Germany
State/province [53] 0 0
Hannover
Country [54] 0 0
Germany
State/province [54] 0 0
Muenchen
Country [55] 0 0
Germany
State/province [55] 0 0
Regensburg
Country [56] 0 0
Germany
State/province [56] 0 0
Siegen
Country [57] 0 0
India
State/province [57] 0 0
Chennai
Country [58] 0 0
India
State/province [58] 0 0
Hyderabaad
Country [59] 0 0
India
State/province [59] 0 0
Kolkatta
Country [60] 0 0
India
State/province [60] 0 0
Mangalore
Country [61] 0 0
India
State/province [61] 0 0
Mumbai
Country [62] 0 0
India
State/province [62] 0 0
Thiruvananthapuram
Country [63] 0 0
India
State/province [63] 0 0
Tirupati
Country [64] 0 0
India
State/province [64] 0 0
Varanasi
Country [65] 0 0
Israel
State/province [65] 0 0
Ashkelon
Country [66] 0 0
Israel
State/province [66] 0 0
Beer Sheva
Country [67] 0 0
Israel
State/province [67] 0 0
Haifa
Country [68] 0 0
Israel
State/province [68] 0 0
Jerusalem
Country [69] 0 0
Israel
State/province [69] 0 0
Petah Tikva
Country [70] 0 0
Israel
State/province [70] 0 0
Tel Aviv
Country [71] 0 0
Israel
State/province [71] 0 0
Tel Hashomer
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Pisa
Country [74] 0 0
Italy
State/province [74] 0 0
Rome
Country [75] 0 0
Japan
State/province [75] 0 0
Fukui
Country [76] 0 0
Japan
State/province [76] 0 0
Fukuoka
Country [77] 0 0
Japan
State/province [77] 0 0
Kagawa
Country [78] 0 0
Japan
State/province [78] 0 0
Kochi
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka
Country [80] 0 0
Japan
State/province [80] 0 0
Tokushima
Country [81] 0 0
Poland
State/province [81] 0 0
Bialystok
Country [82] 0 0
Poland
State/province [82] 0 0
Gdynia
Country [83] 0 0
Poland
State/province [83] 0 0
Lodz
Country [84] 0 0
Poland
State/province [84] 0 0
Lublin
Country [85] 0 0
Poland
State/province [85] 0 0
Poznan
Country [86] 0 0
Poland
State/province [86] 0 0
Warsaw
Country [87] 0 0
South Africa
State/province [87] 0 0
Bellair
Country [88] 0 0
South Africa
State/province [88] 0 0
Bellville
Country [89] 0 0
South Africa
State/province [89] 0 0
Cape Town
Country [90] 0 0
South Africa
State/province [90] 0 0
George
Country [91] 0 0
South Africa
State/province [91] 0 0
Johannesburg
Country [92] 0 0
South Africa
State/province [92] 0 0
Rosebank
Country [93] 0 0
South Africa
State/province [93] 0 0
Somerset West
Country [94] 0 0
South Africa
State/province [94] 0 0
Umhlanga
Country [95] 0 0
Spain
State/province [95] 0 0
Albacete
Country [96] 0 0
Spain
State/province [96] 0 0
Barakaldo
Country [97] 0 0
Spain
State/province [97] 0 0
Barcelona
Country [98] 0 0
Spain
State/province [98] 0 0
Madrid
Country [99] 0 0
Spain
State/province [99] 0 0
Plasencia
Country [100] 0 0
Sweden
State/province [100] 0 0
Malmo
Country [101] 0 0
Sweden
State/province [101] 0 0
Molndal
Country [102] 0 0
Sweden
State/province [102] 0 0
Norrköping
Country [103] 0 0
Sweden
State/province [103] 0 0
Stockholm
Country [104] 0 0
Sweden
State/province [104] 0 0
Uddevalla
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Banes
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Hants
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Merseyside
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Scotland
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Wilts
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Belfast
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Newcastle
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Stoke-On-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no
cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid
(ß-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD
patients are required to have these amyloid plaques in the brain in order to have a
definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (?-secretase) lowers the
production of ß-amyloid. Semagacestat (LY450139) is a functional ?-secretase inhibitor and
was shown to lower ß-amyloid in blood and spinal fluid in humans tested thus far and in
blood, spinal fluid, and brain in animals tested thus far. This study used several different
tests to measure the effect of semagacestat on both ß-amyloid and amyloid plaques for some
participants. The build-up of amyloid plaques was measured by a brain scan that takes a
picture of amyloid plaques in the brain. Other tests measured the overall function of the
brain and brain size in some participants. In this trial, participants who initially received
placebo (inactive sugar pill) were, at a certain point in the study, switched over to active
drug, semagacestat. In other words, all participants could eventually receive active drug.
Participation could last approximately 2 years. Participants taking approved AD medications
were permitted to participate in this study and continue taking these medications during the
study. All participants who completed this study had the option to continue receiving
semagacestat by participating in an open-label study.

Preliminary results from this study (H6L-MC-LFAN [LFAN]) and another similar study
(H6L-MC-LFBC [LFBC; NCT00762411]) showed semagacestat did not slow disease progression and
was associated with worsening of clinical measures of cognition and the ability to perform
activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC, and
open-label H6L-MC-LFBF (LFBF; NCT01035138) were amended to continue collecting safety data,
including cognitive scores, for at least 7 months. The Clinical Trial Registry (CTR) will
reflect results of analyses from the original LFAN protocol in addition to those from the
amended LFAN protocol.
Trial website
https://clinicaltrials.gov/show/NCT00594568
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications